Torvutatug Samrotecan ± Bevacizumab for Ovarian Cancer

(TREVI-OC-03 Trial)

This trial tests a new treatment for individuals with ovarian cancer that has recurred after responding to platinum-based chemotherapy. It evaluates the effectiveness and safety of the drug torvutatug samrotecan, alone or with bevacizumab, compared to standard treatments. The trial targets individuals whose cancer returned at least six months after their last platinum chemotherapy and who have undergone up to two previous cancer treatments. Participants must have a specific type of ovarian cancer and must have completed recent chemotherapy without disease progression. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to a potentially groundbreaking treatment.

Studies have shown that torvutatug samrotecan is generally well-tolerated by patients. Earlier research found that most participants experienced some side effects, but these were usually manageable. For example, many patients had treatment-related side effects, but they were not severe in most cases.

When combined with bevacizumab, torvutatug samrotecan maintains a similar safety profile. Bevacizumab, a drug often used in cancer treatment, has well-known and manageable side effects.

Most treatments for ovarian cancer, like chemotherapy and targeted therapies, work by attacking rapidly dividing cells or targeting specific proteins on cancer cells. But torvutatug samrotecan is unique because it combines a new mechanism with a targeted approach, acting not only on the cancer cells but also enhancing the immune response against the tumor. This treatment is particularly exciting because it can be used alone or in combination with bevacizumab, an established drug that inhibits blood vessel growth in tumors, potentially improving outcomes. Researchers are hopeful that this dual strategy might offer better control over the disease with fewer side effects than existing options.

Research has shown that the drug torvutatug samrotecan may help treat ovarian cancer. In studies, it benefited 24.4% of patients with advanced ovarian cancer that didn't respond to other treatments. While it can delay cancer progression, it does not extend overall survival. In this trial, some participants will receive torvutatug samrotecan either as monotherapy or combined with bevacizumab. Bevacizumab, a drug that slows cancer progression, might extend the time before the cancer worsens when used with torvutatug samrotecan. Experts agree that combining bevacizumab with other ovarian cancer treatments can significantly delay cancer progression and improve survival.²³⁴⁵⁶